ADC Therapeutics SA
ADCT
$1.29
-$0.02-1.15%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 79.58M | 79.18M | 81.36M | 75.21M | 77.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.58M | 79.18M | 81.36M | 75.21M | 77.25M |
| Cost of Revenue | 88.81M | 100.02M | 107.52M | 116.87M | 122.22M |
| Gross Profit | -9.23M | -20.85M | -26.16M | -41.67M | -44.98M |
| SG&A Expenses | 85.33M | 82.03M | 80.23M | 79.67M | 81.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.14M | 182.05M | 187.75M | 196.54M | 203.55M |
| Operating Income | -94.56M | -102.88M | -106.40M | -121.33M | -126.30M |
| Income Before Tax | -97.31M | -136.14M | -141.61M | -165.84M | -168.76M |
| Income Tax Expenses | -404.00K | 850.00K | 1.02M | 1.10M | 1.19M |
| Earnings from Continuing Operations | -96.91 | -136.99 | -142.62 | -166.94 | -169.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.91M | -136.99M | -142.62M | -166.94M | -169.94M |
| EBIT | -94.56M | -102.88M | -106.40M | -121.33M | -126.30M |
| EBITDA | -94.21M | -102.34M | -105.69M | -120.28M | -124.92M |
| EPS Basic | -0.71 | -1.10 | -1.20 | -1.45 | -1.57 |
| Normalized Basic EPS | -0.42 | -0.60 | -0.66 | -0.82 | -0.89 |
| EPS Diluted | -0.71 | -1.10 | -1.20 | -1.45 | -1.57 |
| Normalized Diluted EPS | -0.42 | -0.60 | -0.66 | -0.82 | -0.89 |
| Average Basic Shares Outstanding | 568.93M | 527.66M | 507.69M | 462.79M | 431.17M |
| Average Diluted Shares Outstanding | 568.93M | 527.66M | 507.69M | 462.79M | 431.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |